化合物SCH58261 T6979
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 7
- 0
Product IntroductionBioactivity英文名: SCH 58261描述: SCH 58261 是一种强选择性的竞争性腺苷 A2A 受体拮抗剂，IC50值为 15 nM，对 A2A 受体的选择性分别是 A1、A2B 和
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: SCH 58261
描述: SCH 58261 是一种强选择性的竞争性腺苷 A2A 受体拮抗剂，IC50值为 15 nM，对 A2A 受体的选择性分别是 A1、A2B 和 A3 受体的 323 倍、53 倍、100 倍。
体外活性: SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680. [1]
体内活性: In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. [2] In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance. [3]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 34.5 mg/mL (100 mM)
关键字: Inhibitor | SCH 58261 | inhibit | SCH-58261 | Adenosine Receptor | P1 receptor
相关产品: VPC171 | Kira8 Hydrochloride | Doxofylline | Adenine monohydrochloride hemihydrate | Binodenoson | A2AR-agonist-1 | CHEMBL241987 | AB928 | Cirsimarin | BAY 60-6583
相关库: Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Parkinson's Disease Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Inhibitor Library | GPCR Compound Library | NO PAINS Compound Library
Bioactivity
英文名: SCH 58261
描述: SCH 58261 是一种强选择性的竞争性腺苷 A2A 受体拮抗剂，IC50值为 15 nM，对 A2A 受体的选择性分别是 A1、A2B 和 A3 受体的 323 倍、53 倍、100 倍。
体外活性: SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680. [1]
体内活性: In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. [2] In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance. [3]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 34.5 mg/mL (100 mM)
关键字: Inhibitor | SCH 58261 | inhibit | SCH-58261 | Adenosine Receptor | P1 receptor
相关产品: VPC171 | Kira8 Hydrochloride | Doxofylline | Adenine monohydrochloride hemihydrate | Binodenoson | A2AR-agonist-1 | CHEMBL241987 | AB928 | Cirsimarin | BAY 60-6583
相关库: Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Parkinson's Disease Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Inhibitor Library | GPCR Compound Library | NO PAINS Compound Library
猜你喜欢
感兴趣产品